Compare FirstEnergy Corp. (FE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Gilead Sciences, Inc. — how do they compare? FirstEnergy Corp. trades at $45.06 (market cap $25.95B), while Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 7× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (4.15%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Gilead Sciences, Inc. for 111 Days on average.
| FE | GILD | |
|---|---|---|
Market Cap | $25.95B | $182.40B |
Volume | 5,643,833 | 4,469,821 |
Sector | Utilities | Health |
52-Week High | $51.91 | $155.80 |
52-Week Low | $43.04 | $116.74 |
Typical Hold Time | 71 Days | 111 Days |
Enterprise Value | $54.87B | $205.46B |
Dividend Yield | 4.15% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.00, up 0.94% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, while Q1 beat estimates. Revenue growth has been steady, reaching $15.09B in 2025, with a net income margin of 6.86%. Recent developments include the Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects amid utility sector stability.
Outlook remains cautiously optimistic with a consensus price target of $52.80, representing 17% upside potential. Risks include high debt levels ($24.03B total debt) and regulatory challenges, but strong institutional ownership and analyst buy ratings (42.86%) provide support. The stock offers dividend income with recent declarations of $0.47 per share, appealing to income-focused investors in the electric utility sector.
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
